Teva Pharmaceutical Industries Ltd (ADR) Stock Nasdaq
Stocks
US8816242098
Pharmaceuticals
OTC Markets Traded| Market Cap | 42.89B 36.73B 34.27B 31.44B 59.08B 4,104B 60.25B 407B 158B 2,057B 161B 158B 6,810B | P/E 2026 * |
49.4x | P/E 2027 * | 20.2x |
|---|---|---|---|---|---|
| Enterprise Value | 54.77B 46.9B 43.75B 40.15B 75.44B 5,241B 76.93B 519B 202B 2,627B 206B 201B 8,695B | EV / Sales 2026 * |
3.3x | EV / Sales 2027 * | 2.98x |
| Free-Float |
88.59% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Ltd (ADR)
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 2022-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 2019-12-21 |
Matthew Shields
COO | Chief Operating Officer | 52 | 2024-06-02 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 2008-12-31 |
Sol Barer
CHM | Chairman | 78 | 2017-02-05 |
Rosemary Crane
BRD | Director/Board Member | 65 | 2015-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 43.66B | |
| -2.81% | +2.93% | +76.40% | +127.73% | 1,141B | |
| -2.21% | +2.02% | +49.50% | +55.01% | 659B | |
| -1.56% | +4.39% | +25.19% | +74.39% | 470B | |
| +1.20% | +2.62% | +41.69% | +45.78% | 366B | |
| -0.61% | +2.10% | +23.43% | +41.34% | 302B | |
| +0.32% | +3.25% | +0.94% | +13.42% | 254B | |
| -1.95% | +3.80% | +46.31% | +65.66% | 239B | |
| -1.10% | -0.70% | -14.31% | -52.66% | 207B | |
| -2.82% | +3.84% | +20.81% | +89.04% | 183B | |
| Average | -1.15% | +2.87% | +30.00% | +51.08% | 424.55B | |
| Weighted average by Cap. | -1.62% | +3.12% | +43.48% | +70.86% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.58B 14.2B 13.25B 12.15B 22.84B 1,587B 23.29B 157B 61.26B 795B 62.26B 60.91B 2,633B | 17.3B 14.82B 13.82B 12.68B 23.83B 1,656B 24.3B 164B 63.93B 830B 64.97B 63.56B 2,747B |
| Net income | 1.14B 976M 911M 836M 1.57B 109B 1.6B 10.81B 4.21B 54.69B 4.28B 4.19B 181B | 2.34B 2B 1.87B 1.71B 3.22B 224B 3.28B 22.15B 8.63B 112B 8.77B 8.58B 371B |
| Net Debt | 11.88B 10.17B 9.49B 8.71B 16.36B 1,136B 16.68B 113B 43.88B 570B 44.6B 43.63B 1,886B | 8.61B 7.37B 6.88B 6.31B 11.86B 824B 12.09B 81.6B 31.81B 413B 32.33B 31.63B 1,367B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
